REGULATED PRESS RELEASE published on 07/15/2024 at 17:45, 2 months 4 days ago Disclosure of trading in own shares from July 8th, 2024, to July 12th, 2024 Lagardère SA discloses trading in own shares from July 8th to July 12th, 2024, involving 16,631 shares with a weighted average price of €21.8127 per share Lagardère SA Trading Disclosure Own Shares Weighted Average Price
BRIEF published on 07/09/2024 at 17:50, 2 months 10 days ago LAGARDERE SA Announces Half-Year Liquidity Contract Statement Liquidity Contract Half-year Statement Lagardère SA BNP Paribas Financial Markets
BRIEF published on 07/09/2024 at 17:50, 2 months 10 days ago Bilan semestriel de mise en œuvre du contrat de liquidité de LAGARDERE SA Contrat De Liquidité Transactions Lagardère SA BNP Paribas Marchés Financiers
REGULATED PRESS RELEASE published on 07/09/2024 at 17:45, 2 months 10 days ago Half-year liquidity contract statement LAGARDERE SA announces first half of 2024 liquidity contract details with BNP PARIBAS FINANCIAL MARKETS as per French Financial Markets Authority decision n° 2021-01 Liquidity Contract Lagardère SA French Financial Markets Authority Financial Report BNP PARIBAS FINANCIAL MARKETS
REGULATED PRESS RELEASE published on 07/09/2024 at 17:45, 2 months 10 days ago Bilan semestriel de mise en œuvre du contrat de liquidité Bilan semestriel de mise en œuvre du contrat de liquidité de LAGARDERE SA confié à BNP PARIBAS FINANCIAL MARKETS, conformément à l'AMF. Détails des transactions et volumes au premier semestre 2024 Contrat De Liquidité Bilan Semestriel Lagardère SA Transactions Financières BNP PARIBAS FINANCIAL MARKETS
BRIEF published on 07/08/2024 at 17:50, 2 months 11 days ago Lagardère SA Reports Share Buyback Activity from July 1 to July 5, 2024 Share Buyback Investor Relations LAGARDERE July 2024
BRIEF published on 07/08/2024 at 17:50, 2 months 11 days ago Lagardère SA : Déclaration des Transactions sur Actions Propres Transactions Actions Bourse LAGARDERE Juillet 2024
REGULATED PRESS RELEASE published on 07/08/2024 at 17:46, 2 months 11 days ago Disclosure of trading in own shares from July 1st, 2024, to July 5th, 2024. Detailed information per transaction
REGULATED PRESS RELEASE published on 07/08/2024 at 17:46, 2 months 11 days ago Déclaration des transactions sur actions propres réalisées du 1er juillet 2024 au 5 juillet 2024. Présentation détaillée transaction par transaction
REGULATED PRESS RELEASE published on 07/08/2024 at 17:45, 2 months 11 days ago Disclosure of trading in own shares from July 1st, 2024, to July 5th, 2024 Lagardère SA discloses trading in own shares from July 1st to July 5th, 2024, in compliance with regulations, under a mandate with an investment services provider Trading Disclosure Lagardère SA Own Shares Regulations Investment Services
Published on 09/20/2024 at 09:05, 1 hour 20 minutes ago Nano One Closes on $5 Million Sale of Vacant Land
Published on 09/20/2024 at 02:00, 8 hours 25 minutes ago Academy of Math and Science Celebrates Hispanic Heritage Month
Published on 09/19/2024 at 23:15, 11 hours 10 minutes ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 11 hours 25 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/20/2024 at 09:01, 1 hour 24 minutes ago Original-Research: THE NAGA GROUP AG (von NuWays AG): BUY
Published on 09/20/2024 at 07:30, 2 hours 55 minutes ago XTPL with PLN 5.6 million of commercial sales in H1 2024 and progress on industrial projects - press release
Published on 09/20/2024 at 07:00, 3 hours 25 minutes ago Mister Spex SE: Extraordinary General Meeting adopts all resolutions as proposed by the Company’s Boards
Published on 09/20/2024 at 06:26, 3 hours 59 minutes ago Original-Research: www.warimpex.com (von East Value Research GmbH ):
Published on 09/20/2024 at 08:45, 1 hour 40 minutes ago BAIKOWSKI : Rapport financier semestriel 2024
Published on 09/20/2024 at 08:00, 2 hours 25 minutes ago MEDESIS PHARMA : Résultats encourageants de la première phase de l’essai clinique de phase 2a pour le traitement de la maladie d’Alzheimer avec le NanoLIthium